Last reviewed 2026-06-10 · How we verify

ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy — Treatment Landscape & Competitive Intelligence

ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy (disease) competitive landscape: 1 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across th

Marketed treatment landscape

Approved drugs treating ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

1. Eli Lilly And Co · 1 drug in ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy:

• ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy treatment updates — RSS
• ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy treatment updates — Atom
• ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy treatment updates — JSON

Cite this brief

Drug Landscape (2026). ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/er-positive-her2-negative-esr1-mutated-advanced-or-metastatic-breast-cancer-with-disease-progression-following-at-least-one-line-of-endocrine-therapy. Accessed 2026-06-10.

Related

• ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy full disease profile — treatment pathway, diagnostics, guidelines
• Browse all CI briefs
• Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing